Based on prior preclinical investigations of seribantumab, the maximal inhibition of tumor growth and HER3 is known to be achieved at seribantumab trough concentrations ranging from 100 to 400 mg/L [8]. The gene discussed is ERBB3; the disease is neoplasm.